RXST 📈 Rxsight - Overview

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US78349D1072

RXST: Light Adjustable Lenses, Light Delivery Devices

RxSight, Inc., a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens, a special photosensitive material that changes shape and power. RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California. Web URL: https://www.rxsight.com

Additional Sources for RXST Stock

RXST Stock Overview

Market Cap in USD 1,551m
Sector Healthcare
Industry Medical Devices
GiC Sub-Industry Health Care Supplies
IPO / Inception 2021-07-30

RXST Stock Ratings

Growth 5y 60.0%
Fundamental -30.0%
Dividend -
Rel. Strength Industry -335
Analysts 4.5/5
Fair Price Momentum 32.11 USD
Fair Price DCF -

RXST Dividends

No Dividends Paid

RXST Growth Ratios

Growth Correlation 3m -77.4%
Growth Correlation 12m -22.1%
Growth Correlation 5y 87.2%
CAGR 5y 25.79%
CAGR/Mean DD 5y 1.37
Sharpe Ratio 12m -0.10
Alpha -43.80
Beta 1.09
Volatility 74.12%
Current Volume 468.7k
Average Volume 20d 836.6k
What is the price of RXST stocks?
As of December 28, 2024, the stock is trading at USD 35.05 with a total of 468,673 shares traded.
Over the past week, the price has changed by -8.22%, over one month by -23.90%, over three months by -28.32% and over the past year by -11.27%.
Is Rxsight a good stock to buy?
Probably not. Based on ValueRay Fundamental Analyses, Rxsight (NASDAQ:RXST) is currently (December 2024) not a good stock to buy. It has a ValueRay Fundamental Rating of -30.03 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of RXST as of December 2024 is 32.11. This means that RXST is currently overvalued and has a potential downside of -8.39%.
Is RXST a buy, sell or hold?
Rxsight has received a consensus analysts rating of 4.50. Therefor, it is recommend to buy RXST.
  • Strong Buy: 6
  • Buy: 3
  • Hold: 1
  • Sell: 0
  • Strong Sell: 0
What are the forecast for RXST stock price target?
According to ValueRays Forecast Model, RXST Rxsight will be worth about 35.8 in December 2025. The stock is currently trading at 35.05. This means that the stock has a potential upside of +2.11%.
Issuer Forecast Upside
Wallstreet Target Price 60.5 72.6%
Analysts Target Price 33.8 -3.6%
ValueRay Target Price 35.8 2.1%